Dr. Tim Showalter from ArteraAI presented the data from prostate cancer and discussed possibilities of integrating tissue AI analysis in RCC. Very promising to have AI integration in RCC. #KCRS23 OncoAlert

Can we take lessons learned from #prostatecancer into #kidneycancer ?
Tim Showalter says yes!

KidneyCAN KidneyCANcer KCCure #KCRS23

Thank you for the invitation to share the potential impact we can make together for patients with #RCC #KCRS23 ArteraAI

Amazing work with direct clinical impact! Congrats to Daniel E Spratt NRG Oncology and the team at ArteraAI

Are you passionate about #artificialintelligence and innovation in medical care? Join our team!

Are you looking to make a difference with your career? #ArteraAI is seeking a #ClinicalResearch Associate.

➡️ Get full job details and apply here today: bit.ly/3PhrDVr

So much fun getting to be a shark for this! Exciting to see the potential impact of AI in brachytherapy. Congratulations to all three of the presenters for compelling proposals and pitches.

Shark tank at ABS#2023 presentation on Chat GPT for brachy education ⁦Tim Showalter⁩ ⁦Pranshu Mohindra⁩

Congrats to Kara and the UVA team on completing the trial! Very excited to see the great results

Did you catch Tim Showalter's presentation at #BiomarkersSeries23 ? 🇬🇧

Members of the Artera team met with attendees to discuss how the #ArteraAI #ProstateTest can help identify patients who will benefit from therapy intensification.

➡️ Learn more: artera.ai/our-test/

What if there was a way to identify the patients who would benefit from therapy intensification?

With #ArteraAI , there is. 💙

➡️ Learn more about The ArteraAI #ProstateTest : artera.ai/our-test

The Artera team is heading to #BiomarkersSeries23 2/27-2/28 in Manchester. 🇬🇧

Don't miss Dr. Tim Showalter's presentation 'Pathology-Based Deep Learning Tools to Personalize Treatment Decisions: #ArteraAI #ProstateTest Development & Validation' on 2/27! bit.ly/3XEatCb

🏎️ FORMULA 509 Paul Nguyen #GU23 #pcsm OncoAlert

Salvage RT (med dose 68.4 Gy, 26% nodes tx) w 6 mos ADT ±intensification w AAP/Apa

Overall PFS HR 0.71 p=.06

However pre-specified subgrp PSA>0.5 PFS HR 0.5, P=.03; MFS HR 0.32 p=.02 👉 potential alt to longer ADT in this pop

#ArteraAI is at #GU23 !

Don't miss today's presentation with Daniel E Spratt, as he shares results from six phase III randomized trials and how the use of MMAI prognostic biomarkers may improve the ability to assess risk in patients with #prostatecancer .⚕️ #ASCOGU

Thrilled to see a great turnout for the amazing IBC update from the incomparable Filipa Lynce, MD, FASCO Dana-Farber IBC Program highlighting progress in biology, partnership with Susan G. Komen MD Anderson Cancer Center for diagnosis tools and efforts to move good M1 tx to the M0 IBC setting! #SABCS2022

More science highlights from ASTRO on UroToday! #ASTRO22 #ASTRO2022 #AI #ArteraAI

urotoday.com/conference-hig… via UroToday.com

Our science was highlighted on UroToday! #ASTRO22 #ASTRO2022 #AI #ArteraAI

urotoday.com/conference-hig… via UroToday.com

Fantastic work and beautifully presented @SouMyajiT_RO

Join us at the plenary session to see Dr. Jonathan Tward present 'Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology' at 1:46 PM, Stars at Night Ballroom! #ASTRO22 #ASTRO2022 #AI #ArteraAI